{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:06:48Z","timestamp":1790309208974,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Outcomes of patients with sickle cell disease (SCD) and type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 (GLP1-RA) remain poorly understood. This study evaluated the impact of GLP-1 on adults with SCD and T2DM beyond glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study within the TriNetX Network, identifying adults with SCD and T2DM. GLP-1 users and non\u2013GLP-1 users were matched using Propensity score matching. The index date was defined as the first GLP-1 prescription, and outcomes were assessed over 12 months. Outcomes were major adverse cardiovascular events (MACE), chronic kidney disease (CKD), vaso-occlusive crises (VOC), and hypoglycemia. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 1,391 patients in each cohort, with similar age (48.5 vs. 48.8), and most participants were Black (84.5% vs. 83.8%). GLP-1 therapy was associated with lower risk of MACE (HR 0.61, 95% CI 0.49\u20130.76;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and a reduced risk of stroke (HR 0.47, 95% CI 0.23\u20130.97;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036). Additionally, GLP-1 use was linked to a 36% lower risk of VOC (HR 0.64, 95% CI 0.45\u20130.91;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013). There was no difference in risk of hypoglycemia (HR 1.10, 95% CI 0.60\u20131.76;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.688) or progression to CKD between the two groups (HR 1.26, 95% CI 0.82\u20131.95;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.294).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 therapies demonstrate favorable cardioprotective, vaso stabilizing, and safety benefits in adults with SCD and T2DM, supporting their use in this high-risk population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04322-5","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:07:18Z","timestamp":1774674438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0418-3864","authenticated-orcid":false,"given":"Guy Loic","family":"Nguefang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarpong","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Gyabaah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yussif","family":"Issaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Gabin","family":"Konlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Luna","family":"Landa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-4368","authenticated-orcid":false,"given":"Basile","family":"Njei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"4322_CR1","doi-asserted-by":"crossref","unstructured":"Ware RE, De Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311\u201323.","DOI":"10.1016\/S0140-6736(17)30193-9"},{"issue":"3","key":"4322_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1172\/JCI89741","volume":"127","author":"GJ Kato","year":"2017","unstructured":"Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750\u201360.","journal-title":"J Clin Invest"},{"key":"4322_CR3","doi-asserted-by":"crossref","unstructured":"Piel FB, Steinberg MH, Rees DC. Sickle cell disease. Longo DL, editor. N Engl J Med. 2017;376(16):1561\u201373.","DOI":"10.1056\/NEJMra1510865"},{"key":"4322_CR4","doi-asserted-by":"crossref","unstructured":"Gladwin MT. Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016;387(10037):2565\u201374.","DOI":"10.1016\/S0140-6736(16)00647-4"},{"key":"4322_CR5","doi-asserted-by":"crossref","unstructured":"Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022;5(1):57.","DOI":"10.1001\/jama.2022.10233"},{"issue":"12","key":"4322_CR6","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2337\/dc18-1289","volume":"41","author":"SC Skinner","year":"2018","unstructured":"Skinner SC, Diaw M, Pialoux V, Mbaye MN, Mury P, Lopez P, et al. Increased Prevalence of Type 2 Diabetes\u2013Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait. Diabetes Care. 2018;41(12):2595\u2013602.","journal-title":"Diabetes Care"},{"issue":"1","key":"4322_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bjh.15773","volume":"185","author":"J Zhou","year":"2019","unstructured":"Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, et al. Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population\u2010based cohort analysis. Br J Haematol. 2019;185(1):116\u201327.","journal-title":"Br J Haematol"},{"issue":"20","key":"4322_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","volume":"86","author":"M Galli","year":"2025","unstructured":"Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists. JACC. 2025;86(20):1805\u201319.","journal-title":"JACC"},{"issue":"9","key":"4322_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849\u201370.","journal-title":"Circulation"},{"key":"4322_CR10","doi-asserted-by":"crossref","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374.","DOI":"10.1038\/s41569-023-00849-3"},{"key":"4322_CR11","doi-asserted-by":"crossref","unstructured":"Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the american heart association. Circulation [Internet]. 2022 Mar [cited 2026 Jan 14];145(9). Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001040.","DOI":"10.1161\/CIR.0000000000001040"},{"key":"4322_CR12","doi-asserted-by":"crossref","unstructured":"Zadeh FJ, Fateh A, Saffari H, Khodadadi M, Eslami Samarin M, Nikoubakht N, et al. The vaso-occlusive pain crisis in sickle cell patients: A focus on pathogenesis. Curr Res Translational Med. 2025;73(3):103512.","DOI":"10.1016\/j.retram.2025.103512"},{"key":"4322_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","volume":"111","author":"M Almutairi","year":"2019","unstructured":"Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides. 2019;111:26\u201332.","journal-title":"Peptides"},{"issue":"5","key":"4322_CR14","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326(5):H1159\u201376.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4322_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.niox.2024.05.003","volume":"149","author":"AR Pavan","year":"2024","unstructured":"Pavan AR, Terroni B, Dos Santos JL. Endothelial dysfunction in Sickle Cell Disease: Strategies for the treatment. Nitric Oxide. 2024;149:7\u201317.","journal-title":"Nitric Oxide"},{"issue":"8","key":"4322_CR16","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/dom.14399","volume":"23","author":"JJH Bray","year":"2021","unstructured":"Bray JJH, Foster-Davies H, Salem A, Hoole AL, Obaid DR, Halcox JPJ, et al. Glucagon\u2010like peptide\u20101 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta\u2010analysis of randomised controlled trials. Diabetes Obes Metabolism. 2021;23(8):1806\u201322.","journal-title":"Diabetes Obes Metabolism"},{"issue":"5","key":"4322_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH De Boer","year":"2022","unstructured":"De Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974\u201389.","journal-title":"Kidney Int"},{"key":"4322_CR18","doi-asserted-by":"crossref","unstructured":"Sasaki T, Giang SML, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dialysis Trans. 2025;22:gfaf193.","DOI":"10.1093\/ndt\/gfaf116.0511"},{"key":"4322_CR19","doi-asserted-by":"crossref","unstructured":"Rangaswami J, Bhalla V, De Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American heart association. Circulation [Internet]. 2020 Oct 27 [cited 2026 Jan 15];142(17). Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000920.","DOI":"10.1161\/CIR.0000000000000935"},{"issue":"10","key":"4322_CR20","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.2337\/dci23-0036","volume":"46","author":"DB Sacks","year":"2023","unstructured":"Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark \u00c5, et al. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023;46(10):e151\u201399.","journal-title":"Diabetes Care"},{"issue":"6","key":"4322_CR21","doi-asserted-by":"publisher","first-page":"bqaf082","DOI":"10.1210\/endocr\/bqaf082","volume":"166","author":"JL Zapater","year":"2025","unstructured":"Zapater JL, Nicholoff ST, Sweis NS, Saraf SL, Layden BT. Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease. Endocrinology. 2025;166(6):bqaf082.","journal-title":"Endocrinology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04322-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:07:01Z","timestamp":1775128021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4322"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04322-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No external assistance was sought or received for the design, execution, analysis, or reporting of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Assistance with the study"}},{"value":"This work has not been previously presented elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentation"}},{"value":"The authors declare that they have no conflicts of interest, financial or otherwise, relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"126"}}